MyCellSafe™
Autologous cell banking for future medical use
DevelopmentActive
Key Facts
Indication
Autologous cell banking for future medical use
Phase
Development
Status
Active
Company
About MygoGenesis
Founded in 2018 and based in San Diego, MygoGenesis is a private, pre-revenue biotech developing a novel cellular reprogramming platform. Its core technology, the Mygotic Process™, claims to create totipotent cells from a patient's own somatic cells, potentially bypassing challenges associated with iPSCs or embryonic stem cells. The company is pursuing a diversified strategy, aiming to spin out subsidiary companies focused on specific applications like universal blood production, cell banking, and sustainable reagents for endotoxin testing.
View full company profile